Gettin’ In The Game Junior National Championship
We are very excited to have the opportunity to send two representatives of the Hemophilia Foundation of Maryland to the CSL Behring Getting in the Game Junior National Championship (JNC).
FDA Approval Includes Full ALTUVIIIO™ Pediatric Trial Results
The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for ALTUVIIIO™ (Sanofi) to include the full results of the phase 3 XTEND-Kids clinical trial. ALTUVIIIO is a recombinant factor VIII therapy (rFVIII), developed with proprietary Fc fusion technologies to
Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
PARAMUS, NJ. 29/04/2024. PRESS RELEASE Octapharma USA, Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis
Upcoming CareFirst Formulary Updates and Medications Added to Prior Authorization List
Carefirst has issued a Medical Preferred Drug Strategy Update effective August 1, 2024. Below is a summary of the factor agents affected. Learn what this means for affected patients.
Hemophilia Foundation of Maryland (HFM)
13 Class Court Parkville, MD 21234
